FDA lays out postmarketing approaches for data collection from underrepresented groups
The FDA on Thursday published draft guidance on considerations for postmarket studies on populations that were underrepresented in premarket trials.
The agency tells sponsors to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
